Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 576 • 2018 ACR/ARHP Annual Meeting
An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis
Satoshi Ito¹, Yoichi Kurossawa^1,2, Eriko Hasegawa^1,2, Daisuke Kobayashi^1,2, Shinji Taniguhi¹, Asami Abe¹, Hiroshi Otani¹, Kiyoshi Nakazono¹, Akira Murasawa¹, Ichiei Narita² and Hajime Ishikawa¹, ¹Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: HOPEFUL-1 trial showed efficacy of combination therapy with adalimumab (ADA) plus methotrexate (MTX) in MTX naïve patients with active early rheumatoid arthritis (eRA). In…
Abstract Number: 2873 • 2018 ACR/ARHP Annual Meeting
Remaining Pain and Widespread, Non-Inflammatory Pain Distribution during the First 12 Months after RA Diagnosis
Yvonne C. Lee¹, Orit Schieir², Marie-France Valois³, Susan J. Bartlett⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol A Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Janet E. Pope¹¹ and Vivian P. Bykerk¹², ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²McGill University, Montreal, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Toronto, Newmarket, ON, Canada, ¹¹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹²Hospital for Special Surgery, New York, NY
Background/Purpose: The incidence of fibromyalgia is highest in the first 12 months after RA diagnosis,1 indicating that this period may represent a critical window during…
Abstract Number: 588 • 2018 ACR/ARHP Annual Meeting
Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: The ACR Hybrid, officially recommended by the ACR as a revision to the ACR20/50/70 response criteria, combines the ACR20/50/70 scores with the mean percent…
Abstract Number: 2898 • 2018 ACR/ARHP Annual Meeting
Increased Frequency of Circulating CD4+CXCR5-PD1hi Peripheral Helper T (cTph) Cells in Patients with Seropositive Early Rheumatoid Arthritis (RA)
Paula Fortea-Gordo¹, Laura Nuño², Alejandro Villalba², Diana Peiteado³, Irene Monjo⁴, Paloma Sanchez-Mateos⁵, Amaya Puig-Kröger⁶, Alejandro Balsa¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain
Background/Purpose: A novel population of CD4+ T cells with B cell helping capacity has been described in the synovial tissues and peripheral blood of seropositive…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 2984 • 2018 ACR/ARHP Annual Meeting
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol Hitchon⁵, Louis Bessette⁶, Gilles Boire⁷, Carter Thorne⁸, Janet E. Pope⁹, Vivian P. Bykerk¹⁰, Edward C. Keystone¹¹, Diane Tin¹² and Glen Hazlewood¹³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³McGill University, Montreal, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Toronto, Newmarket, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Implementation of RA guidelines have improved remission outcomes in RA; nevertheless 45% of early RA participants do not achieve remission in the first year.…
Abstract Number: 922 • 2017 ACR/ARHP Annual Meeting
Biologic DMARD Prescribing Patterns in Elderly Patients with Rheumatoid Arthritis
Britney Jones¹, Imran Hassan², Walter P. Maksymowych³ and Elaine Yacyshyn⁴, ¹University of Alberta, Edmonton, AB, Canada, ²EPICORE Centre, University of Alberta, Edmonton, AB, Canada, ³Department of Rheumatology, University of Alberta, Edmonton, AB, Canada, ⁴Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis is a chronic inflammatory process involving progressive destruction of joints. Currently, 30% of rheumatoid arthritis (RA) patients are over the age of…
Abstract Number: 2015 • 2017 ACR/ARHP Annual Meeting
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. Α Monocentric Preliminary Study
Alberto Batticciotto¹, Giada Prato², Marco Antivalle², Maria Chiara Ditto¹, Maria Chiara Gerardi², Rossella Talotta², Federica Rigamonti², Fabiola Atzeni¹ and Piercarlo Sarzi-Puttini², ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy
Background/Purpose: A number of studies have demonstrated that musculoskeletal ultrasonography (MSUS) is more sensitive in diagnosing arthritis than clinical examination although, as underlined in a…
Abstract Number: 955 • 2017 ACR/ARHP Annual Meeting
In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Tiziana Piepoli¹, Mario Montagna¹, Daniele Maggioni¹, Silvia Zerbi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio C. Rovati², ¹Rottapharm Biotech, Monza, Italy, ²Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086 is a selective EP4 receptor antagonist immunomodulator in clinical development for rheumatoid arthritis (RA). In animal models of RA, it demonstrated a superior…
Abstract Number: 2042 • 2017 ACR/ARHP Annual Meeting
Referral Criteria to an Early Arthritis Clinic: Poor Agreement between Referring Physicians and Rheumatologists
Filipa Farinha^1,2, Gisela Eugénio², Mary Marques², Francisco Freitas³, José António P. da Silva^2,4 and Cátia Duarte^2,4, ¹Rheumatology, Centro Hospitalar do Baixo Vouga, E.P.E., Aveiro, Portugal, ²Rheumatology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ³Centre for Social Studies, Universidade de Coimbra, Coimbra, Portugal, ⁴Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal
Background/Purpose: Prompt identification and referral of patients with suspected inflammatory arthritis to a rheumatology clinic are crucial for early diagnosis and treatment. In the referral…
Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting
Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
Keith Knapp^1,2, Eric Mueller^1,2 and Gary Craig^1,2, ¹Arthritis Northwest PLLC., Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
Abstract Number: 2375 • 2017 ACR/ARHP Annual Meeting
Does the Body Mass Index Have Any Influence in the Characteristics of Early Arthritis Patients?
Pablo Moreno Fresneda¹, Lola Martínez-Quintanilla Jiménez¹, Ana M. Ortiz Garcia², Eva Tomero³, Rosario García-Vicuña⁴ and Isidoro Gonzalez-Alvaro², ¹Rheumatology, Rheumatology Division, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain, ²Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ³Hospital La Princesa. Madrid., Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain
Background/Purpose: Obesity has been proposed as a risk factor to develop rheumatoid arthritis (RA) and it has been associated with a worse response to several…
Abstract Number: 1253 • 2017 ACR/ARHP Annual Meeting
Patient Reported Outcomes Explain the Lack of Agreement between Physician and Patient Perceived Remission in Early Rheumatoid Arthritis
Samina A. Turk^1,2, Linda A. Rasch³, Willem F. Lems^4,5, Lilian van Tuyl³, Dirkjan van Schaardenburg^4,6 and Marieke M. Ter Wee^5,7, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, ⁷Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients increasingly reach a state of absence of disease activity, or remission. However, the proportion of patients classified as in remission…
Abstract Number: 2390 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort
Stephanie Gottheil¹, Orit Schieir², Carter Thorne³, Carol A Hitchon⁴, Diane Tin⁵, Edward C. Keystone⁶, Gilles Boire⁷, Boulos Haraoui⁸, Susan J. Bartlett⁹, Vivian P. Bykerk¹⁰ and Janet E. Pope¹¹, ¹University of Western Ontario, LONDON, ON, Canada, ²McGill University, Montreal, ON, Canada, ³University of Toronto, Newmarket, ON, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸Institute de Rheumatologie, Montreal, QC, Canada, ⁹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ¹⁰2-005, Mt Sinai Hospital, Toronto, ON, Canada, ¹¹Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada
Background/Purpose: RA patients are at a high risk of osteoporosis and fracture, in part due to frequent glucocorticoid use. Despite recommendations from ACR guidelines on…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…

« Previous Page
1
…
3
4
5
6
7
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.